Gallic acid-grafted chitooligosaccharides suppress antigen-induced allergic reactions in RBL-2H3 mast cells

• Published in: European journal of pharmaceutical sciences Vol. 47; no. 2; pp. 527 - 533
• Main Authors: Vo, Thanh-Sang, Ngo, Dai-Hung, Kim, Se-Kwon
• Format: Journal Article
• Language: English
• Published: Kindlington Elsevier B.V 29.09.2012; Elsevier
• Subjects: Allergic reaction; Animals; Anti-Allergic Agents - pharmacology; Antigens - immunology; Biological and medical sciences; Calcium - metabolism; Cell Line; Cell Survival - drug effects; Chitooligosaccharides; Cytokines - immunology; Dinitrophenols - immunology; Gallic acid; Gallic Acid - analogs & derivatives; Gallic Acid - pharmacology; General pharmacology; Histamine; Histamine Release - drug effects; Immunoglobulin E - immunology; Mast Cells - drug effects; Mast Cells - immunology; Medical sciences; Mitogen-Activated Protein Kinases - immunology; NF-kappa B - immunology; Oligosaccharides - pharmacology; Pharmaceutical technology. Pharmaceutical industry; Pharmacology. Drug treatments; Rats; RBL-2H3 mast cells; Receptors, IgE - immunology; Serum Albumin, Bovine - immunology; Histamine; Gallic acid; Allergic reaction; Chitooligosaccharides; RBL-2H3 mast cells; Antigen; Immunopathology; Allergy; Pharmaceutical technology; Toxicity; Mast cell
• ISSN: 0928-0987; 1879-0720
• DOI: 10.1016/j.ejps.2012.07.010

In this study, a bioactive derivative of chitooligosaccharides (3–5kDa) was synthesized via grafting of gallic acid onto chitooligosaccharides (G-COS) to enhance anti-allergic activity. Hence, G-COS was evaluated for its capabilities against allergic reactions in RBL-2H3 mast cells sensitized with dinitrophenyl-specific immunoglobulin E antibody and stimulated by antigen dinitrophenyl-bovine serum albumin. It was revealed that G-COS exhibited significant inhibition on histamine release and production as well as intracellular Ca2+ elevation at the concentration of 200μg/ml. Likewise, the suppressive effects of G-COS on expression and production of interleukin (IL)-4 and tumor necrosis factor (TNF)-α were evidenced. Moreover, G-COS treatment caused a remarkable blockade on degradation of inhibitory κB-α (IκB-α) protein, translocation of nuclear factor (NF)-κB, and phosphorylation of mitogen-activated protein kinases (MAPKs). Notably, the inhibitory activities of G-COS on allergic reactions were found as a consequence of suppression of FcεRI expression in antigen-stimulated cells. Accordingly, G-COS was suggested to be a promising candidate of novel inhibitors against allergic reactions.